Cancer pathogenesis and therapy最新文献

{"title":"Multi-disciplinary surgery for simultaneous resection of multiple tumors in a patient with newly diagnosed metastatic pheochromocytoma/paraganglioma","authors":"Jibo Jing,&nbsp;Lingfeng Meng,&nbsp;Yaoguang Zhang,&nbsp;Runhua Tang,&nbsp;Haoran Wang,&nbsp;Jiaxing Ning,&nbsp;Xinhao Wang","doi":"10.1016/j.cpt.2023.05.003","DOIUrl":"https://doi.org/10.1016/j.cpt.2023.05.003","url":null,"abstract":"<div><p>Metastatic pheochromocytoma/paraganglioma (MPP) is a rare endocrine tumor that originates from extra-adrenal chromaffin cells such as the paraganglia cells of sympathetic and parasympathetic nerves. It usually causes multiple solid tumors and exhibits strong aggressiveness with poor prognosis, with a reported 5-year survival rate of less than 50%. Cases of brain and retroperitoneal metastases at the initial diagnosis have not yet been reported. We report a 41-year-old male patient initially diagnosed with MPP in the brain and retroperitoneum who underwent multi-disciplinary collaborative surgery and simultaneous removal of two tumors at our center. Postoperative pathology revealed infiltrative growth of a skull base tumor. The patient chose to receive the tyrosine kinase inhibitor sunitinib as a targeted treatment. A 3-month follow-up after surgery showed that the patient recovered well without signs of metastasis or recurrence. We present multi-disciplinary surgery under similar circumstances for enhanced treatment and postoperative management. The patient demonstrates a favorable prognosis during postoperative follow-up, indicating that simultaneous multidisciplinary surgery may offer greater benefits for MPP patients.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49710434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncofertility: Treatment options from bench to bedside","authors":"Divya Gupta ,&nbsp;Shubham Singh ,&nbsp;Sangeeta Shukla ,&nbsp;Sadhana Shrivastava","doi":"10.1016/j.cpt.2023.05.001","DOIUrl":"https://doi.org/10.1016/j.cpt.2023.05.001","url":null,"abstract":"<div><p>In recent years, there has been continuous improvement in the treatment and diagnosis of cancer, which has led to a significant improvement in the survival rate of cancer patients. Treatments that include chemotherapy, radiotherapy, surgery, or combined therapy have several side effects that may lead to premature ovarian insufficiency in females or substantial male germ cell loss. Reproductive biologists recommend that all patients who are diagnosed with a malignant tumor must undergo a consultation for fertility protection and preservation. In this review, we discuss the background knowledge, methods, and options for fertility preservation and how these new strategies help oncologists, surgeons, pediatricians, and hematologists, conserve fertility and be aware of the concepts, methods, and importance of fertility guards. This review may aid in the advancement of novel personalized methods for fertility preservation according to patients’ conditions.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49705411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of interstitial lung disease with the use of programmed cell death 1 (PD-1) inhibitor compared with programmed cell death ligand 1 (PD-L1) inhibitor in patients with breast cancer: A systematic review and meta-analysis","authors":"Lijuan Guo ,&nbsp;Xiaoyi Lin ,&nbsp;Xin Lin ,&nbsp;Yulei Wang ,&nbsp;Jiali Lin ,&nbsp;Yi Zhang ,&nbsp;Xiangqing Chen ,&nbsp;Miao Chen ,&nbsp;Guochun Zhang ,&nbsp;Yifang Zhang","doi":"10.1016/j.cpt.2023.08.002","DOIUrl":"10.1016/j.cpt.2023.08.002","url":null,"abstract":"<div><h3>Background</h3><p>Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have become integral elements within the current landscape of breast cancer treatment modalities; however, they are associated with interstitial lung disease (ILD), which is rare but potentially fatal. Notably, only a few studies have compared the difference in ILD incidence between PD-1 and PD-L1 inhibitors. Therefore, this study aimed to assess the discrepancies regarding ILD risk between the two immune checkpoint inhibitors. We also reported three cases of ILD after PD-1 inhibitor treatment.</p></div><div><h3>Methods</h3><p>We comprehensively searched PubMed, EMBASE, and the Cochrane Library to identify clinical trials that investigated PD-1/PD-L1 inhibitor treatment for patients with breast cancer. Pooled overall estimates of incidence and risk ratio (RR) were calculated with a 95% confidence interval (CI), and a mirror group analysis was performed using eligible studies.</p></div><div><h3>Results</h3><p>This meta-analysis included 29 studies with 4639 patients who received PD-1/PD-L1 inhibitor treatment. A higher ILD incidence was observed among 2508 patients treated with PD-1 inhibitors than among 2131 patients treated with PD-L1 inhibitors (0.05 <em>vs.</em> 0.02). The mirror group analysis further revealed a higher ILD event risk in patients treated with PD-1 inhibitors than in those treated with PD-L1 inhibitors (RR = 2.34, 95% CI, 1.13–4.82, <em>P</em> = 0.02).</p></div><div><h3>Conclusion</h3><p>Our findings suggest a greater risk of ILD with PD-1 inhibitors than with PD-L1 inhibitors. These findings are instrumental for clinicians in treatment deliberations, and the adoption of more structured diagnostic approaches and management protocols is necessary to mitigate the risk of ILD.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000496/pdfft?md5=66a896a8554fb3348fbec20454111765&pid=1-s2.0-S2949713223000496-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74080886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of negatively correlated miR-205-5p/HMGB3 and miR-96-5p/FOXO1 on the diagnosis of breast cancer and benign breast diseases","authors":"Jiaying Li ,&nbsp;Shuang Peng ,&nbsp;Xuan Zou ,&nbsp;Xiangnan Geng ,&nbsp;Tongshan Wang ,&nbsp;Wei Zhu ,&nbsp;Tiansong Xia","doi":"10.1016/j.cpt.2023.04.002","DOIUrl":"https://doi.org/10.1016/j.cpt.2023.04.002","url":null,"abstract":"<div><h3>Background</h3><p>MicroRNA (miRNA) and mRNA levels in matching specimens were used to identify miRNA–mRNA interactions. We aimed to integrate transcriptome, immunophenotype, methylation, mutation, and survival data analyses to examine the profiles of miRNAs and target mRNAs and their associations with breast cancer (BC) diagnosis.</p></div><div><h3>Methods</h3><p>Based on the Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA), differentially expressed miRNAs and targeted mRNAs were screened from experimentally verified miRNA-target interaction databases using Pearson's correlation analysis. We used real-time quantitative reverse transcription polymerase chain reaction to verify BC and benign disease samples, and logistic regression analysis was used to establish a diagnostic model based on miRNAs and target mRNAs. Receiver operating characteristic curve analysis was performed to test the ability to recognize the miRNA-mRNA pairs. Next, we investigated the complex interactions between miRNA-mRNA regulatory pairs and phenotypic hallmarks.</p></div><div><h3>Results</h3><p>We identified 27 and 359 dysregulated miRNAs and mRNAs, respectively, based on the GEO and TCGA databases. Using Pearson's correlation analysis, 10 negative miRNA-mRNA regulatory pairs were identified after screening both databases, and the related miRNA and target mRNA levels were assessed in 40 BC tissues and 40 benign breast disease tissues. Two key regulatory pairs (miR-205-5p/High mobility group box 3 (<em>HMGB3</em>) and miR-96-5p/Forkhead Box O1 (<em>FOXO1</em>)) were selected to establish the diagnostic model. They also had utility in survival and clinical analyses.</p></div><div><h3>Conclusions</h3><p>A diagnostic model including two miRNAs and their respective target mRNAs was established to distinguish between BC and benign breast diseases. These markers play essential roles in BC pathogenesis.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49705401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examined lymph node numbers influence prognosis in rectal cancer treated with neoadjuvant therapy","authors":"Liyu Zhu ,&nbsp;Lin Wang ,&nbsp;Zhidong Gao ,&nbsp;Yujian Zeng ,&nbsp;Kaixiong Tao ,&nbsp;Quan Wang ,&nbsp;Xinming Li ,&nbsp;Huanhu Zhang ,&nbsp;Zhanlong Shen ,&nbsp;Jing Zhou ,&nbsp;Kai Shen ,&nbsp;Yingjiang Ye ,&nbsp;Aiwen Wu","doi":"10.1016/j.cpt.2023.01.001","DOIUrl":"https://doi.org/10.1016/j.cpt.2023.01.001","url":null,"abstract":"<div><h3>Background</h3><p>The number of lymph nodes examined (LNe) is often insufficient in patients with rectal cancer (RC) treated with neoadjuvant therapy; however, its prognostic value remains controversial. Thus, we retrospectively explored whether LNe had an influence on staging and prognosis and investigated whether there was a cut-off value for better prognosis in patients with RC treated with neoadjuvant therapy.</p></div><div><h3>Methods</h3><p>Data were collected from seven prospective hospital databases in China from July 2002 to May 2018. Binary logistic regression models were used to predict lymph node metastasis. The cut-off value for LNe was determined using X-tile 3.6.1. Survival outcomes and risk factors were analyzed using the log-rank test and Cox regression model.</p></div><div><h3>Results</h3><p>A total of 482 patients were included, of whom 459 had complete overall survival (OS) information. Using the percentile method, the total number of lymph nodes examined (TLNe) was 14–16 (40th–60th percentile), and the proportion of patients with lymph node metastasis reached a maximum of 48.1%. Cox multivariate analysis showed that the odds ratio (OR) remained the highest when TLNe was 14–16 (OR = 3.379, <em>P</em> = 0.003). The 3-year and 5-year OS were 85.4% and 77.8%, respectively. Negative lymph nodes examined (NLNe) of ≤6 was an independent risk factor for 3-year and 5-year OS (3-year OS 71.1% <em>vs.</em> 85.9%, <em>P</em> = 0.004; 5-year OS 66.3% <em>vs.</em> 74.3%, <em>P</em> = 0.035). Subgroup analysis for patients with ypN + showed that higher 3-year and 5-year OS were achieved when the TLNe was &gt;10, 78.8% <em>vs.</em> 54.0% (<em>P</em> = 0.005), and 60.8% <em>vs.</em> 36.0% (<em>P</em> = 0.012), respectively. Patients with ypN₀M₀ had a higher 5-year OS when the TLNe was &gt;19 (<em>P</em> = 0.055).</p></div><div><h3>Conclusion</h3><p>The TLNe and NLNe influenced the staging accuracy and demonstrated prognostic value in patients with RC treated with neoadjuvant therapy.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49705405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of diffuse large B-cell lymphoma with interstitial pneumonia","authors":"Ge Song ,&nbsp;Changxi Zhou ,&nbsp;Shuxia Wang ,&nbsp;Tianqi Tao ,&nbsp;Weiping Guan ,&nbsp;Xuan Wu ,&nbsp;Ping Zhu ,&nbsp;Bo Yang ,&nbsp;Xuechun Lu","doi":"10.1016/j.cpt.2023.06.001","DOIUrl":"https://doi.org/10.1016/j.cpt.2023.06.001","url":null,"abstract":"<div><p>This report involves a 54-year-old female patient diagnosed with diffuse large B-cell lymphoma who developed interstitial pneumonia (IP) during treatment. The patient presented to the ward with enlarged lymph nodes in the neck and was treated with the standard regimen, which included rituximab, cyclophosphamide, doxorubicin liposomes, vincristine, and prednisone (R-CDOP regimen). After 3 cycles, the treatment was assessed as effective. However, following the 4th cycle, the patient experience shortness of breath after physical activity. A repeat lung computer tomography indicated IP, which completely recovered after receiving “full coverage” treatment. Subsequently, the patient underwent 2 cycles of cyclophosphamide, doxorubicin liposomes, vincristine, and prednisone (CDOP), followed by local radiotherapy. Currently, the patient is now being followed up with regular reviews.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49710441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis","authors":"Bakhya Shree,&nbsp;Koyel Das,&nbsp;Vivek Sharma","doi":"10.1016/j.cpt.2022.12.003","DOIUrl":"https://doi.org/10.1016/j.cpt.2022.12.003","url":null,"abstract":"<div><p>Prostate cancer (PCa) is the most common malignancy in men. Despite aggressive therapy involving surgery and hormonal treatments, the recurrence and emergence of metastatic castration-resistant prostate cancer (CRPCa) remain a major challenge. Dysregulation of the transforming growth factor-β <strong>(</strong>TGF-β) signaling pathway is crucial to PCa development and progression. This also contributes to androgen receptor activation and the emergence of CRPC. In addition, TGF-β signaling regulates long non-coding RNA (lncRNA) expression in multiple cancers, including PCa. Here, we discuss the complex regulatory network of lncRNAs and TGF-β signaling in PCa and their potential applications in diagnosing, prognosis, and treating PCa. Further investigations on the role of lncRNAs in the TGF-β pathway will help to better understand PCa pathogenesis.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49710433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between high body mass index and prognosis of patients with early-stage breast cancer: A systematic review and meta-analysis","authors":"Zhoujuan Li ,&nbsp;Guoshuang Shen ,&nbsp;Mingqiang Shi ,&nbsp;Yonghui Zheng,&nbsp;Yumei Guan,&nbsp;Yuanfang Xin,&nbsp;Miaozhou Wang,&nbsp;Fuxing Zhao,&nbsp;Dengfeng Ren,&nbsp;Jiuda Zhao","doi":"10.1016/j.cpt.2023.03.002","DOIUrl":"https://doi.org/10.1016/j.cpt.2023.03.002","url":null,"abstract":"<div><h3>Background</h3><p>A high body mass index (BMI) can indicate overweight or obesity and is a crucial risk factor for breast cancer survivors. However, the association between high BMI and prognosis in early-stage breast cancer (EBC) remains unclear. We aimed to assess the effects of high BMI on the prognosis of patients with EBC.</p></div><div><h3>Methods</h3><p>The PubMed, Embase, and Cochrane Library databases and proceedings of major oncological conferences related to the effects of BMI on the prognosis of breast cancer were searched up to November 2021. Fixed- and random-effects models were used for meta-analyses. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for disease-free survival (DFS) and overall survival (OS) were extracted from the included literature.</p></div><div><h3>Results</h3><p>Twenty retrospective cohort studies with 33,836 patients with EBC were included. Overweight patients had worse DFS (HR: 1.16, 95% CI: 1.05–1.27, <em>P</em> = 0.002) and OS (HR: 1.20; 95% CI: 1.09–1.33, <em>P</em> &lt; 0.001). Obesity also had adverse effects on DFS (HR: 1.17, 95% CI: 1.07–1.29, <em>P</em> = 0.001) and OS (HR: 1.30, 95% CI: 1.17–1.45, <em>P</em> &lt; 0.001). Likewise, patients with high BMI had worse DFS (HR: 1.16, 95% CI: 1.08–1.26, <em>P</em> &lt; 0.001) and OS (HR: 1.25, 95% CI: 1.14–1.39, <em>P</em> &lt; 0.001). In subgroup analyses, overweight had adverse effects on DFS (HR: 1.11, 95% CI: 1.04–1.18, <em>P</em> = 0.001) and OS (HR: 1.18, 95% CI: 1.11–1.26, <em>P</em> &lt; 0.001) in multivariate analyses, whereas the relationship that overweight had negative effects on DFS (HR: 1.21, 95% CI: 0.99–1.48, <em>P</em> = 0.058) and OS (HR: 1.39, 95% CI: 0.92–2.10, <em>P</em> = 0.123) was not statistically significant in univariate analysis. By contrast, obesity had adverse effects on DFS (HR: 1.21, 95% CI: 1.06–1.38, <em>P</em> = 0.004 and HR: 1.14, 95% CI: 1.08–1.22, <em>P</em> &lt; 0.001) and OS (HR: 1.33, 95% CI: 1.15–1.54, <em>P</em> &lt; 0.001 and HR: 1.23, 95% CI: 1.15–1.31, <em>P</em> &lt; 0.001) in univariate and multivariate analyses, respectively.</p></div><div><h3>Conclusions</h3><p>Compared with normal weight, increased body weight (overweight, obesity, and high BMI) led to worse DFS and OS in patients with EBC. Once validated, these results should be considered in the development of prevention programs.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49710436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomaterial-based in vitro 3D modeling of glioblastoma multiforme","authors":"Tanvir Ahmed","doi":"10.1016/j.cpt.2023.01.002","DOIUrl":"https://doi.org/10.1016/j.cpt.2023.01.002","url":null,"abstract":"<div><p>Adult-onset brain cancers, such as glioblastomas, are particularly lethal. People with glioblastoma multiforme (GBM) do not anticipate living for more than 15 months if there is no cure. The results of conventional treatments over the past 20 years have been underwhelming. Tumor aggressiveness, location, and lack of systemic therapies that can penetrate the blood–brain barrier are all contributing factors. For GBM treatments that appear promising in preclinical studies, there is a considerable rate of failure in phase I and II clinical trials. Unfortunately, access becomes impossible due to the intricate architecture of tumors. <em>In vitro</em>, bioengineered cancer models are currently being used by researchers to study disease development, test novel therapies, and advance specialized medications. Many different techniques for creating <em>in vitro</em> systems have arisen over the past few decades due to developments in cellular and tissue engineering. Later-stage research may yield better results if <em>in vitro</em> models that resemble brain tissue and the blood–brain barrier are used. With the use of 3D preclinical models made available by biomaterials, researchers have discovered that it is possible to overcome these limitations. Innovative <em>in vitro</em> models for the treatment of GBM are possible using biomaterials and novel drug carriers. This review discusses the benefits and drawbacks of 3D <em>in vitro</em> glioblastoma modeling systems.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49705410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ketogenic dietary intervention as therapy for thrombocytopenia","authors":"Yue Wu,&nbsp;Xiaojun Chen","doi":"10.1016/j.cpt.2023.01.004","DOIUrl":"https://doi.org/10.1016/j.cpt.2023.01.004","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49710445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}